Developing an innovative molecule requires more than demonstrating promising biological activity. Success depends on building a development strategy that considers chemistry, safety, quality, manufacturability, and scalability from the earliest stages of the program.

Many development challenges that emerge during clinical manufacturing or commercialization can be traced back to decisions made long before the first GMP batch is produced. When manufacturability considerations are delayed, development teams often face process redesigns, additional studies, regulatory complications, and extended timelines.

Olon helps companies identify and address these risks early by combining process development expertise, analytical knowledge, manufacturing experience, and a global network of scientific resources to support molecules from development through commercialization.

Why Early API Development Decisions Matter

One of the most common sources of risk in small molecule development is relying on discovery chemistry approaches too far into the development process.

Discovery routes are designed for generating functional group diversity for evaluation. They are not necessarily designed for safety, scalability, impurity control, cost efficiency, or commercial manufacturing. As programs advance, these limitations become increasingly difficult to overcome.

Once toxicology studies and GMP manufacturing begin, significant process changes become more challenging. New impurities may require additional evaluation. Manufacturing strategies may need to be revisited. Regulatory documentation may need to be updated. In the worst cases, entire studies may need to be repeated.

Addressing these considerations before toxicology and GMP production helps establish a stronger foundation for the entire development program with minimal upfront cost and time.  Failing to do so may get you to Phase I faster but will cost exponentially more in Phase II and III.

Identifying Risks Before They Become Problems

Many indicators of future manufacturing challenges can be detected early.

Solubility limitations, crystallization challenges, mixing issues, low-yield reactions, unstable intermediates, hazardous reaction conditions, and poor impurity control often signal that a process may encounter difficulties during scale-up.

Purification strategies can also create future obstacles. Processes that rely heavily on column chromatography may perform adequately at laboratory scale but often require substantial redevelopment before commercial manufacturing becomes feasible.

Operational exposure is another critical consideration. As you start to consider moving into larger-scale GMP production, CDMOs require increasingly more information on the safety of the compounds to properly evaluate the exposure banding of the APIs.  Failing to account for this could generate significant delays, limit manufacturing options, and impact development costs.

Evaluating these factors early during process development allows potential failure modes to be identified before they affect timelines and budgets.

Building Robust Processes Through Cross-Functional Expertise

Successful API development requires collaboration across multiple disciplines.

Process chemists, analytical scientists, safety specialists, engineers, manufacturing experts, and quality professionals each contribute critical perspectives to development decisions. Actions taken by one group frequently influence outcomes for another.

Analytical strategies influence process design. Process decisions affect manufacturing operations. Engineering considerations impact scalability. Quality requirements guide development activities throughout the program.

Olon USA integrates these functions early in development to create robust manufacturing routes that address process performance, impurity control, raw material strategy, safety requirements, scalability, and product quality simultaneously.

This approach helps reduce technical risk while improving long-term manufacturability.

Evaluating Scalability from the Beginning

A route that performs well at gram scale does not automatically translate to successful commercial production.

Olon evaluates synthetic routes through the lens of commercial viability. Process chemists and route scouting specialists assess scalability, efficiency, safety, raw material availability, and manufacturing practicality before programs advance.

When limitations are identified, alternative approaches can be explored early. Route redesign, process optimization, and new manufacturing strategies can often be implemented before they become costly development obstacles.

Rapid route assessment allows development teams to determine whether an existing process can support future manufacturing needs or whether modifications are necessary to create a more scalable solution.

Early Intervention Can Change the Trajectory of a Program

The impact of early API expertise is often most visible when a development program encounters challenges before reaching GMP manufacturing.

In one project, a large pharmaceutical company approached Olon with a ten-step synthetic route that had already been evaluated by multiple external vendors in Asia. After a year of development work, the program had not produced a practical path forward for manufacturing. The route presented scalability challenges, and the development timeline continued to expand without a clear solution because the focus from these vendors was speed, not a scalable process.

Olon conducted a technical assessment of the process and identified opportunities to redesign the route and improve overall manufacturability. By leveraging our process chemistry expertise, route scouting capabilities, and cross-functional development resources, the team established a shorter 6-step process that was more robust and produced the toxicology batch within four months.

The program continued to advance rapidly. Multiple GMP manufacturing batches followed shortly thereafter, quickly scaling from 4 kg to 12 kg to 25-35 kg quantities within the first year.

The outcome was not driven by a single process improvement. It resulted from evaluating scalability, process robustness, impurity control, manufacturing requirements, and development strategy before those issues became larger obstacles. The earlier these assessments occur, the more options development teams have available to address risk efficiently.

Supporting Highly Potent and Complex Molecules

The increasing number of highly potent APIs entering development creates additional challenges for manufacturing and scale-up.

Containment requirements, occupational exposure limits, specialized equipment, and production planning must all be considered as part of the development strategy.

Olon’s high-potency capabilities support programs from early development through commercial manufacturing. Development activities can begin with gram-scale quantities and progress through GMP manufacturing while maintaining appropriate containment controls and process oversight.

By integrating development and manufacturing capabilities within a coordinated framework, potent compounds can advance through development with greater confidence and fewer operational risks.

Leveraging a Global Network of Scientific Expertise

Scientific challenges rarely fit neatly within a single discipline.

Olon’s global network includes 14 R&D centers, One innovation hub, and over 200 R&D experts across multiple areas of specialization. This structure allows development teams to access the expertise required for specific technical challenges as they arise.

Process development activities can be supported by analytical specialists, safety experts, statistical design professionals, manufacturing teams, and subject matter experts located throughout the organization.

This collaborative model accelerates problem-solving, expands access to specialized technologies, and allows multiple development activities to occur simultaneously. The result is faster decision-making and more efficient development programs.

Consistency Across Development and Commercial Manufacturing

Risk reduction extends beyond process development.

Quality systems, regulatory support, analytical methodologies, and manufacturing strategies must remain aligned throughout the lifecycle of a molecule.

Olon operates within a unified quality and regulatory framework across its global network. This consistency helps ensure that development decisions remain aligned with future manufacturing and regulatory requirements and readily transfer processes within the network.

A successful API program requires more than producing material. It requires creating a process that is scientifically sound, well-documented, reproducible, and capable of supporting future clinical and commercial needs.

Choosing an API Development Partner

Selecting an API development partner should involve more than comparing project costs.

Development teams should evaluate whether a potential partner understands the technical challenges associated with their molecule and can provide meaningful guidance before work begins. Technical discussions conducted early in the evaluation process often reveal potential risks, opportunities for process improvement, and alternative approaches that can improve scalability and long-term manufacturability.

The lowest initial quote does not always translate into the lowest overall development cost. Technical issues that are identified early can often be resolved quickly. When those same issues are discovered later, they can lead to delays, additional development work, and increased program costs.

The most valuable development partners ask difficult questions early. They identify risks before they become problems. They provide technical recommendations before manufacturing starts. They focus on creating scalable, robust processes that support long-term success.

Beyond technical expertise, companies should evaluate whether a partner can support the molecule throughout its lifecycle. Development programs evolve. Manufacturing requirements change. Regulatory expectations increase. Working with a partner that can provide continuity from toxicology batches through clinical development and commercial manufacturing can help reduce complexity as a program advances.

Start the Conversation Early

The decisions made before a toxicology batch is manufactured often influence the trajectory of the entire development program.

Olon combines process chemistry expertise, analytical capabilities, manufacturing experience, quality oversight, engineering support, and a global network of scientific resources to help companies identify risks before they become costly delays.

By bringing process chemists, analytical scientists, safety specialists, manufacturing experts, engineers, and quality professionals into development discussions early, Olon helps build manufacturing strategies designed for scalability, regulatory readiness, and long-term success.

Whether a program requires route scouting, process optimization, high-potency development, scale-up support, or a complete path from development through commercialization, Olon provides the expertise and resources needed to move innovative molecules forward with confidence.

Contact Olon USA today to start a technical discussion about your molecule, evaluate potential development risks, and explore strategies that can support a more efficient path to clinical and commercial manufacturing.